KBC Group NV Has $2.21 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

KBC Group NV lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after selling 11,944 shares during the quarter. KBC Group NV's holdings in Natera were worth $2,207,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in NTRA. Fulton Bank N.A. increased its position in Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares during the last quarter. QRG Capital Management Inc. increased its stake in shares of Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares during the last quarter. Colonial Trust Co SC increased its stake in shares of Natera by 7.8% during the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after purchasing an additional 96 shares during the last quarter. Silvercrest Asset Management Group LLC increased its stake in shares of Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock worth $445,000 after purchasing an additional 98 shares during the last quarter. Finally, Utah Retirement Systems increased its stake in shares of Natera by 1.6% during the 4th quarter. Utah Retirement Systems now owns 6,200 shares of the medical research company's stock worth $981,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on NTRA. Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Barclays increased their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Piper Sandler increased their price target on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $184.63.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider owned 130,205 shares of the company's stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at $1,358,628.48. This represents a 34.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,272 shares of company stock valued at $8,345,368 over the last ninety days. Company insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $3.07 during trading on Monday, hitting $158.69. 754,178 shares of the stock were exchanged, compared to its average volume of 1,422,379. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The company's fifty day simple moving average is $160.45 and its 200-day simple moving average is $158.42. The company has a market capitalization of $21.67 billion, a price-to-earnings ratio of -107.95 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm's revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.56) EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.